Melanie Magnan
Overview
Explore the profile of Melanie Magnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Condamine B, Morel-Journel T, Tesson F, Royer G, Magnan M, Bernheim A, et al.
ISME J
. 2024 Dec;
19(1.
PMID: 39665373
Escherichia coli is an increasingly antibiotic-resistant opportunistic pathogen. Few data are available on its ecological and evolutionary dynamics in its primary commensal niche, the vertebrate gut. Using Illumina and/or Nanopore...
2.
Massenet J, Weiss-Gayet M, Bandukwala H, Bouchereau W, Gobert S, Magnan M, et al.
iScience
. 2024 Dec;
27(12):111350.
PMID: 39650736
In Duchenne muscular dystrophy (DMD), muscle stem cells' (MuSCs) regenerative capacities are overwhelmed leading to fibrosis. Whether MuSCs have intrinsic defects or are disrupted by their environment is unclear. We...
3.
Marin J, Walewski V, Braun T, Dziri S, Magnan M, Denamur E, et al.
mSphere
. 2024 Oct;
9(10):e0053024.
PMID: 39365076
a commensal species of the human gut, is an opportunistic pathogen that can reach extra-intestinal compartments, including the bloodstream and the bladder, among others. In non-immunosuppressed patients, purifying or neutral...
4.
Amoura A, Pistien C, Chaligne C, Dion S, Magnan M, Bridier-Nahmias A, et al.
Cell Host Microbe
. 2024 May;
32(6):900-912.e4.
PMID: 38759643
Urinary tract infection (UTI), mainly caused by Escherichia coli, are frequent and have a recurrent nature even after antibiotic treatment. Potential bacterial escape mechanisms include growth defects, but probing bacterial...
5.
dHumieres C, Delavy M, Alla L, Ichou F, Gauliard E, Ghozlane A, et al.
Microbiome
. 2024 Mar;
12(1):50.
PMID: 38468305
Background: Antibiotics notoriously perturb the gut microbiota. We treated healthy volunteers either with cefotaxime or ceftriaxone for 3 days, and collected in each subject 12 faecal samples up to day...
6.
Couce A, Limdi A, Magnan M, Owen S, Herren C, Lenski R, et al.
Science
. 2024 Jan;
383(6681):eadd1417.
PMID: 38271521
The distribution of fitness effects of new mutations shapes evolution, but it is challenging to observe how it changes as organisms adapt. Using lineages spanning 50,000 generations of evolution, we...
7.
Allain M, Maherault A, Gachet B, Martinez C, Condamine B, Magnan M, et al.
Antimicrob Agents Chemother
. 2023 Sep;
67(10):e0011123.
PMID: 37702541
Multiresistance plasmids belonging to the IncI incompatibility group have become one of the most pervasive plasmid types in extended-spectrum beta-lactamase-producing of animal origin. The extent of the burden imposed on...
8.
Jacquier H, Assao B, Chau F, Guindo O, Condamine B, Magnan M, et al.
J Infect
. 2023 Jun;
87(3):199-209.
PMID: 37369264
Objective: Whole genome sequencing (WGS) of extended-spectrum β-lactamase-producing Escherichia coli (ESBL-E. coli) in developing countries is lacking. Here we describe the population structure and molecular characteristics of ESBL-E. coli faecal...
9.
Camelena F, Poncin T, Magnan M, Jacquier H, Merimeche M, Bercot B
Int J Antimicrob Agents
. 2022 Jul;
60(3):106634.
PMID: 35830946
No abstract available.
10.
Hobson C, Vigue L, Magnan M, Chassaing B, Naimi S, Gachet B, et al.
Front Cell Infect Microbiol
. 2022 Jun;
12:886447.
PMID: 35719352
Background: Anticancer drug efficacy is linked to the gut microbiota's composition, and there is a dire need to better understand these interactions for personalized medicine. microbiota models are promising tools...